Definium Therapeutics, Inc.

NASDAQ: DFTX · Healthcare · Biotechnology

PublicHQ New York, NY · New YorkCIK 0001813814Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 58DQ —GM —SS 67

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, market scale · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$183.8M

Employees

106

as of 2026-08-07

Market cap

$5.0B

as of 2026-08-07

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$183.8M-$183.8M2025

Operating income-$166.3M-$166.3M2025

Total assets$440.1M$440.1M2025

Liabilities$107.8M$107.8M2025

Equity$332.3M$332.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Definium Therapeutics, Inc.’s financial profile?

Definium Therapeutics, Inc. earned -$183.8M in FY2025 net income.

Peers · Healthcare

Vaxcyte, Inc.——Belite Bio, Inc——Erasca, Inc.——Dyne Therapeutics, Inc.——Edgewise Therapeutics, Inc.——Celcuity Inc.——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEORobert Barrow

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York, NY

ExchangeNASDAQ: DFTX

Employees106

IPO date2016-11-15

Latest filings

8-K2026-08-12 10-Q2026-08-06 8-K2026-08-06 8-K2026-06-24 8-K2026-06-22 8-K2026-06-12 8-K2026-05-19 8-K2026-05-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.